USA ma ansixin insuliintii Novo

Shirkadda deenishka ee dawooyinka, Novo Nordiske, ayaa indhaha ku kala qaaday hayadda caafimaadka Maraykanka, FDA, oo ka rabta baadhitaan dheeraad ah oo shirkaddu ku samayso dawooyinkeeda insuliinta ee  Tresiba iyo Ryzodeg.

Sidaas waxa goor danbe oo habeenimadii axadda ah suuqa ganacsiga alaabada ka sheegay shirkadda Novo Nordiske.

Hayadda caafimaadka Maraykanka, FDA, ayaa soo qortay waraaq faahfaahsan oo jawaabcelin ah, iyadoo caddaysay in aan la ansixin karin labadaas dawo, iyadoo arrintaasi saamayn ku yeelan doonta xisaabaha sheikadda Novo.

Niyadjab
Suuqa Maraykanka ayaa ahmiyad wayn u lahaa shirkadda, labada dawo ee ansixintooda la baajiyayna waxay kaalin wayn kaga jireen dakhliga ay sayladdaas mustaqbalka ka helayso shirkaddu.

Laakiin hadda waxa filayaa, in la samayn doono cilmibaadhis dheeraad ah, ka hor inta aan labadaas dawo loo iibgayn Maraykanka.

- Waraaqdaas waannu la yaabnay, niyadjabna way nagu keentay, laakiin waannu tixgelinaynaa goaanka hayadda caafimaadka Maraykanka, FDA, iyo sidii aannu u xallili lahayn waxyaabaha hortaagan in la soo gebogebeeyo wadaxaajoodka aannu hayadda kala gelaynno codsiga diiwaangelinta, ayuu sheegay agaasimaha shirkadda, Lars Rebien Sørensen.

- Waxa aannu ku qanacsan nahay, in dawooyinka Tresiba iyo Ryzodeg waxtar wayn u leeyihiin dadka u baahan insuliinta, ayuu ku sheegay farriinta uu u gudbiyay suuqa ganacsiga alaabada.

EU-da oo ansixisay
Shirkadda Novo Nordiske ayaa sheegtay, in aan la filin, in baadhitaanku soo gebogebaysmo sannadkan lagu jiro.

Shirkadda Novo Nordiske ayaa bishii Janaweri ka heshay xaashida ansixinta dawooyinka Tresiba og Ryzodeg komishanka EU-da, sidoo kale alabadaas dawo waa laga ansixiyay Japan.

Diidmada Hayadda caafimaadka maraykanku saamayn wayn ku yeelan mayso xisaabaha shirkadda ee sannadka 2013.